Bukwang Pharm, Up 8.87% Amid Rising Theme of COVID-19 (Treatment/Vaccine Development)

On the 18th, the COVID-19 (treatment/vaccine development, etc.) theme rose by 3.03% compared to the previous day, showing strength, while Bukwang Pharmaceutical, which is attracting attention as a related stock, surged by 8.87% compared to the previous day. Bukwang Pharmaceutical is known as a manufacturer of pharmaceuticals and quasi-drugs (such as toothpaste).

[Graph] Major stock price changes in the COVID-19 (treatment/vaccine development, etc.) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Bukwang Pharmaceutical's quant financial score is 18.05 points, with higher stability and profitability scores than the average of other stocks related to the COVID-19 (treatment/vaccine development, etc.) theme, ranking 11th within the theme. This indicates that Bukwang Pharmaceutical's ability to respond to internal and external economic environment changes and its efficient profit-generating capability are better compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.